)
Zoetis (ZTS) investor relations material
Zoetis Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q2 2026 revenue was $2.5 billion, nearly flat year-over-year, with adjusted net income of $781 million, down 1–2% organically, and net income of $691 million, down 5% reported; U.S. Companion Animal faced pressure from lower clinic visits, price sensitivity, and increased competition, while International, Livestock, and Diagnostics segments grew.
Leadership changes included appointments of Jay Saccaro as EVP, CFO, and COO, and Abhay Nayak as EVP and President of U.S. Commercial Operations to drive execution.
Commercial strategy was adapted, with investments focused on innovation and high-return opportunities.
Portfolio advanced with new product launches and acquisitions, including VitalRADS and launches of Lenivia and Portela in the EU, Canada, and Great Britain.
FY 2026 guidance revised downward due to persistent market headwinds and competitive pressures.
Financial highlights
Q2 global revenue was $2.5 billion, flat reported and down 1% organically; adjusted net income was $781 million, down 2% organically; adjusted diluted EPS was $1.87, up 4–5% year-over-year.
U.S. segment revenue was $1.3 billion, down 7% year-over-year; International segment revenue was $1.2 billion, up 6–8%.
Adjusted gross margin was 72.9%, down 40 bps reported; U.S. gross margin was 83.1%, international 71.0%.
Adjusted SG&A expenses were $586 million, down 3–4% year-over-year; adjusted R&D expenses increased 4–5%.
Restructuring and acquisition/divestiture-related costs rose to $77 million in Q2, mainly from employee termination costs.
Outlook and guidance
Full-year 2026 revenue guidance revised to $9.12–$9.32 billion, representing a 3% to 1% organic operational decline.
Adjusted net income expected at $2.57–$2.62 billion, down 9% to 5% organically; adjusted diluted EPS guided to $6.15–$6.25.
Guidance reflects persistent competitive and pricing pressures, especially in U.S. Companion Animal, and assumes no near-term market stabilization.
Reported diluted EPS expected at $5.55–$5.65.
- Strong growth, innovation, and channel expansion offset tariff risks and competitive pressures.ZTS
Stifel Jaws & Paws Conference 2025 - Tariff impacts are managed, innovation and alternative channels drive sustained growth.ZTS
BNP Paribas 2nd Annual Animal Health Day - Above-market growth driven by innovation, strong franchises, and strategic R&D investment.ZTS
Piper Sandler 36th Annual Healthcare Conference - Driving animal health innovation and growth with global scale, R&D, and strong shareholder returns.ZTS
Corporate presentation - Innovation pipeline and global diversification drive growth despite macro and competitive headwinds.ZTS
46th Annual William Blair Growth Stock Conference - 2026 growth guided at 2%-5%, with innovation and targeted promotions offsetting competition.ZTS
Stifel Jaws & Paws Conference 2026 - Solid growth, innovation focus, and recovery plans highlighted amid competitive pressures.ZTS
AGM 2026 - Q3 2024 delivered 14% operational revenue growth and raised guidance, led by key franchises.ZTS
Q3 2024 - Q1 2025 saw 9% organic revenue growth and raised adjusted EPS guidance to $6.20–$6.30.ZTS
Q1 2025
Next Zoetis earnings date
Next Zoetis earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage